logo Covalent Drug Discovery Summit
logo Covalent Drug Discovery Summit

Nobody has claimed this event yet.

Organizers who claim their event pages can update listing details, add photos, answer to reviews, view click reports and more.

Claim your free event listing

Accelerating Screening and Discovery of Potent Covalent Inhibitors and Degraders with Improved Triaging, Selectivity and Safety for Targeting Hard-to-Drug Targets

Public International Twice a year or more

The field of targeted covalent therapeutics is seeing a surge of activity, with both new and established companies investing heavily in the space. The inaugural Covalent Drug Discovery Summit has been built alongside industry experts to provide a dedicated forum to tackle associated challenges and advance covalent therapeutics; previously only afforded a small feature in larger 'small molecule' conferences.

As the very first meeting solely focused on covalent therapeutics, the 18+ speaker faculty boasts leaders from large pharma, new biotech and academia. This is the summit to meet 80+ covalency experts gathering to solve target selectivity, hit screening, lead optimization, and covalent warhead design to carve out covalency's niche for targeting the "undruggable" proteome.

Brochure: https://go.evvnt.com/1900494-0?pid=5528

Time: 7:30 AM - 5:00 PM

Speakers: Alun Bermingham, Senior Vice President and Head of Platform, Totus Medicines, Anthony Rullo, Associate Professor of Medicine and Chemical Biology, McMaster University, Brent Martin, Vice President - Head of Chemical Biology, Scorpion Therapeutics, Brian Lanman, Director of Research, Amgen, David Weinstein, Vice President and Head of Chemistry, Vividion Therapeutics, Eranthie Weerapana, Professor of Chemistry, Boston College, Herman Lik Hang Yuen, Associate Director, DEL Informatics and Cheminformatics, Nurix, Ivan Cornella, Chief Scientific Officer, Covant Therapeutics, Jeff McKenna, Director of Hit Generation and Covalent Drug Discovery, Novartis AG, Jeffrey Martin, Principal Scientist, Biogen, John Knox, Vice President - Structural Chemistry and Discovery Sciences, Revolution Medicines Inc., Laura D’Agostino, Vice President of Chemistry, Dunad Therapeutics, Lei Wang, Professor, University of Califorina, San Francisco, Neil Dhawan, Chief Executive Officer, Totus Medicines, Ping Cao, Chief Executive Officer, Bridgene Biosciences, Ruben Tommasi, Chief Scientific Officer, Dunad Therapeutics, Simona Cotesta, Director of Global Discovery Chemistry, Novartis, Stephen Baker, Head Of Chemistry Reactive, Biosciences, Thorsten Kirschberg, Executive Vice President of Chemistry, Biomea Fusion, Tinghu Zhang, Senior Scientist, (Nathanael Gray’s Lab) Stanford University, Ziyang Zhang, Professor of Chemistry and Chemical Biology, University of California Berkeley

logo Covalent Drug Discovery Summit
logo user

Share your own experience

Covalent Drug Discov...

Reviews are public and modifiable.

Satisfaction Indicators from ratings shared by attendees


Ratings & Reviews for Covalent Drug Discovery Summit